title: Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?
authors.affiliation: Molecular Endocrinology Group, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. graham.williams@imperial.ac.uk.
authors.forename: Graham R
authors.initials: GR
authors.lastname: Williams
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D010024:Osteoporosis / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D018570:Risk Assessment; D013961:Thyroid Gland / Q000187:drug effects / Q000528:radiation effects / Q000601:surgery; D013964:Thyroid Neoplasms / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery*; D013972:Thyrotropin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013974:Thyroxine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D013972:Thyrotropin; D013974:Thyroxine